BCOS

Our mission is to promote research, best clinical practice and a wider understanding of the effects of cancer treatment on the cardiovascular system.

[BCOS @BCOSCardioOnc]

This will inform future discussions and funding applications for collaborative UK cardio-oncology research. For further information, please contact [email protected].

[BCOS @BCOSCardioOnc]

Please take 10 minutes to complete this short survey (https://t.co/NHvVQgzQBf), which seeks to gain an overview of opinions from UK-based healthcare professionals in relation to cardio-oncology research priorities.

[American College of Cardiology @ACCinTouch]

The PROACT trial found adding enalapril to standard care during chemotherapy did not prevent cardiotoxicity in patients receiving high-dose anthracycline-based chemotherapy.

Read more on the trial: https://t.co/WPIPe6UM8N #ACCLATAM

[BSEcho @BSEcho]

We are highlighting the sessions you can expect at BSEcho 2024 - we're excited to see you in Edinburgh!

See the programme for our cardio-oncology session in association with @BCOSCardioOnc

👇 View the full programme and book on our website: https://t.co/Vw1lO2C7VN

[Professor Arjun Ghosh (London Cardio-Oncology) @arjunkg]

This joint @BritishCardioSo @BCOSCardioOnc and @UCLH Cancer Academy course will give the attendee an update in contemporary cardio-oncology practice and will cover recent updates in cardio-oncology.
https://t.co/LOJsWWVk63

[International Cardio-Oncology Society @ICOSociety]

#GCOS2024 is going to be packed with talks from leading voices around the world including @BlaesAnneMD, Dr Alexander Lyon, Dr Bonnie Ky, and many more.

See the Full Lineup: https://t.co/wlDT9RaF6U

Don't miss out - save your spot: https://t.co/62Rglzsgzy

#cardioonc

[JACC Journals @JACCJournals]

In this #JACCCardioOnc review, Dr. @DavidGGent, et al cover the breadth of what is known about #CVD in the adult #HCT population, focusing on acute & late complications, risk prediction, surveillance, & treatment of complications. https://t.co/khVvFpz3dE #CardioOnc

[BCOS @BCOSCardioOnc]

Food for thought. Are the historical anthracycline conversion ratios still appropriate for use in contemporary clinical practice and research?

https://t.co/rjqFDLTKQR

[BCOS @BCOSCardioOnc]

SCE (HF, cardiogenic shock or MI) in 16% & ☠️ in 53% at last f/u.

SCE associated w/ ⬆️ overall mortality (HR 2.8; 95% CI 1.6 - 4.7) and non-relapse mortality (HR 3.5; 95% CI 1.4 - 8.8).

☠️ associated w/ ⬆️ IL-6 and ferritin after CAR-T, SCE also associated w/ ⬆️ CRP & trop.

[BCOS @BCOSCardioOnc]

A selection of the 10 best cardio-oncology papers this year (in no particular order...)🎁🎄🎅 @CircAHA @escardio @ehj_ed @JACCJournals @NatureMedicine @JAMA_current @ICOSociety @CD_AACR @ACPUK @BritSocHaem @TheBHF

[BCOS @BCOSCardioOnc]

10. Biomarkers and cardiovascular outcomes in CAR T-cell therapy recipients

❓Multi-centre registry study examining the association between CAR-T related severe CV events (SCE) and mortality.

🏥202 patients w/ anti-CD19 CAR-T, median f/u 297 days.

https://t.co/jlow77Qk8Y